Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Fisetin

3,3',4',7-tetrahydroxyflavone

Animal replicated

OTCFlavonoid Senolytic Small Molecule

RouteOralGray-market only

Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance

What it is: 3,3',4',7-tetrahydroxyflavone — Natural Flavonoid Senolytic — Flavonoid, Senolytic, Small Molecule.
Why people use it: Used primarily for longevity and anti-aging.
What the evidence supports: The fundamental issue: fisetin's evidence is distributed across two categories that are not equivalent. Category 1 — Preclinical (Grade B-C): cell culture senolytic activity; mouse lifespan extension; neuroprotection in multiple models; ex vivo human adipose tissue activity. Category 2 — Human (Grade E/X for senolytic; Grade B-C for safety): human safety confirmed in trials; COVID-19 safety/feasibility confirmed; no published human senolytic tissue data; ITP failure in mice suggests the primary finding may not be as robust as marketed. Community users are predominantly acting on Category 1 evidence while the supplement industry markets with Category 1 language. Category 2 is what actually matters for the community's use case — and it does not yet support fisetin's marketed claims.

If you only read one thing

Fisetin became the world's best-selling senolytic supplement on the basis of one landmark mouse study from a credible lab. That study was genuinely good science — but the community extrapolation from 'extends lifespan in old mice' to 'reverses senescence in humans' has outrun the evidence. The ITP failed to replicate the lifespan finding. The human trials are complete or ongoing but unpublished. The bioavailability problem — fisetin is rapidly metabolized with poor oral bioavailability, raising serious questions about whether supplement doses achieve senolytic plasma concentrations in humans — is barely discussed in community or supplement industry discourse. The community is correctly excited about a promising compound with a solid preclinical basis. It is incorrectly treating that preclinical basis as clinical validation.

Check interactions →

Published literature

1human RCT1human study5animal4in vitro

Human counts reflect safety/feasibility and non-senolytic pilot evidence only; as of the current chapter, published in-vivo human senolytic endpoint data remain absent.

Evidence reality check

Human evidence

2 human studies

1 randomized; 1 observational.

Preclinical base

9 lab signals

5 animal; 4 in-vitro/mechanistic.

Evidence snapshot

The fundamental issue: fisetin's evidence is distributed across two categories that are not equivalent. Category 1 — Preclinical (Grade B-C): cell culture senolytic activity; mouse lifespan extension; neuroprotection in multiple models; ex vivo human adipose tissue activity. Category 2 — Human (Grade E/X for senolytic; Grade B-C for safety): human safety confirmed in trials; COVID-19 safety/feasibility confirmed; no published human senolytic tissue data; ITP failure in mice suggests the primary finding may not be as robust as marketed. Community users are predominantly acting on Category 1 evidence while the supplement industry markets with Category 1 language. Category 2 is what actually matters for the community's use case — and it does not yet support fisetin's marketed claims.

From the chapter quick-reference block.

Fisetin is the world's most accessible senolytic — and the best illustration of the gap between compelling preclinical evidence and validated clinical benefit.

The central tension resolved: A 2018 paper from a credible lab showed fisetin was the most potent senolytic among ten flavonoids, extended lifespan in mice, and showed senolytic activity in human tissue explants ex vivo. The supplement industry built a large market on this. The ITP — the most rigorous independent mouse longevity test in existence — failed to significantly replicate the lifespan finding. Multiple Mayo Clinic human trials designed to show fisetin reduces senescent cell burden in living humans have been running since 2018 and have not published their primary senolytic data as of May 2026. Fisetin has a significant bioavailability problem that may prevent oral supplement doses from achieving senolytic plasma concentrations in humans. The community is using a supplement whose best evidence is a mouse study that failed independent replication, while the human evidence that would settle the question remains unpublished.

What fisetin clearly is: a safe, anti-inflammatory, SIRT1-activating, mTOR-inhibiting flavonoid with a strong neuroprotective preclinical profile that operates at lower concentrations than may be required for senolysis. These non-senolytic effects have a meaningful independent evidence base from multiple labs over 15+ years. Users who take fisetin and experience benefits may be responding to these lower-concentration effects regardless of whether senolysis is occurring.

What fisetin may be: a genuine natural senolytic that, with appropriate formulation and dosing, clears a meaningful fraction of senescent cells in human tissues. The 2018 paper is genuinely compelling, and ex vivo human adipose tissue activity is more meaningful than pure animal data. The community's intuition may be biologically correct even if the clinical validation is pending.

What fisetin is not: a validated human senolytic in 2026. The human trials exist. Their results will matter. Until those results are published, community use is based on extrapolation from preclinical data — biologically coherent, bioavailability-uncertain, and clinically unvalidated.

Categories

Longevity & Anti-aging

Properties

✓ Human RCTNot injectable

Half-life

(4) Rapidly cleared from plasma with a short half-life (~1-2 hours in rats)

Evidence

CAnimal replicated

Mechanism (Senolytic)

Fisetin inhibits multiple pro-survival pathways that protect senescent cells from apoptosis: PI3K/Akt/mTOR (reduces anti-apoptotic signaling); BCL-2 and BCL-XL (anti-apoptotic protein inhibition, similar to Quercetin but with different binding affinities); MDM2 (p53 tumor suppressor pathway); and HSP90 (heat shock protein that stabilizes BCL-2 family members in senescent cells). The combination makes fisetin a 'broad-spectrum' senolytic against multiple pro-survival mechanisms simultaneously.

Mechanism (Non-Senolytic)

Fisetin has a longer independent research history as a neuroprotective, anti-inflammatory, and antioxidant compound predating the senolytic literature. Established mechanisms: SIRT1 activation (histone deacetylase/longevity signaling); mTOR inhibition (extends lifespan in model organisms independently of senolysis); BDNF upregulation; NF-κB suppression; direct radical scavenging. These non-senolytic effects are relevant to its overall longevity and neuroprotective profile.

THE LANDMARK STUDY — AND ITS LIMITATIONS

Yousefzadeh et al. (EBioMedicine, 2018, Kirkland/Mayo group): fisetin was the most potent senolytic among 10 flavonoids tested. Extended median and maximum lifespan of aged wild-type mice. Reduced senescence markers in multiple tissues. Most importantly: showed senolytic activity in human adipose tissue explants (ex vivo). This study drove enormous community interest. CRITICAL CONTEXT: The ITP (NIA Interventions Testing Program), which represents the gold standard of rigorous independent mouse longevity testing, tested fisetin. The results were not significantly positive — fisetin did not significantly extend lifespan in the ITP study. This failure is less discussed in the community than the 2018 paper.

THE HUMAN EVIDENCE GAP

As of May 2026: NO PUBLISHED STUDY has demonstrated that fisetin reduces senescent cell burden in living humans. The Mayo Clinic has conducted and/or is conducting multiple human fisetin trials (AFFIRM, AFFIRM-LITE, NCT04771611, and others). These trials began as early as 2018. Their primary senolytic endpoint data has not been published. Fight Aging! commentary (September 2025) notes: 'there is still no published data of [fisetin's] senolytic capacity in humans.' The community is using fisetin based on a mouse study and ex vivo human tissue data, without published clinical validation.

THE BIOAVAILABILITY PROBLEM

Fisetin has notoriously poor and variable oral bioavailability. It is rapidly metabolized — primarily to glucuronide and sulfate conjugates — in the gut wall and liver. Plasma fisetin concentrations after typical oral doses (100-500 mg) are low and highly variable. The senolytic concentrations demonstrated in cell culture require plasma levels that may not be achievable with standard oral supplementation. This pharmacokinetic limitation is the most underappreciated challenge in fisetin's clinical translation — and is rarely mentioned in supplement marketing.

Community Dosing

Most common: 500-2,000 mg/day orally for 2 consecutive days per cycle (the 'pulsed' senolytic protocol). Some users take it daily. The 2-day protocol mirrors the 'hit-and-run' senolytic dosing concept — high enough for a short burst to disable senescent cell survival pathways, then cleared. No validated human dose exists.

WADA Status

Not listed on the 2026 WADA Prohibited List. Athletes can use without WADA violation.

FDA Status

Not FDA-approved for any indication. OTC dietary supplement; FDA GRAS for the flavonoid class generally. Senolytic indication: unapproved.

Comparison to D+Q

Fisetin is the accessible, prescription-free alternative to D+Q. No drug interactions, no ECG required, no prescription needed, much cheaper. These advantages are real. But D+Q has direct human tissue evidence of senescent cell reduction; fisetin does not. D+Q and fisetin are at very different positions on the evidence spectrum despite being marketed as equivalent senolytics.

Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this class Compare 4 side by side →

Dasatinib + Quercetin

Same class · Flavonoid

The Only Senolytic With Real Human Trial Data. Tested at the Mayo Clinic. Proven to Clear Senescent Cells in Humans. Dasatinib Is a Chemotherapy Drug. The Community Is Using It Without Prescriptions, ECGs, or Drug Interaction Screens.

J-147

Same class · Small Molecule

The Drug That Reversed Brain Aging in Mice. Discovered by Phenotypic Screen. Target Unknown for 7 Years. ATP Synthase: The Unexpected Bridge Between Alzheimer's and Aging. BDNF Induction. AMPK/mTOR via a Completely Novel Entry Point. Phase 1 Human Safety Trial Completed (NCT03838185). The Compound That Is Structurally Related to Curcumin But Pharmacologically Nothing Like It.

Metformin